{ "run": { "id": "cmnr12ihm02cmp658ckehw5wo", "region": "US", "assetId": "cmnr12ih902cip658gn1xvrxy", "ticker": "BAX", "snapshotId": "cmnr12ihe02ckp658s6rb290h", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:47.480Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12ihe02ckp658s6rb290h", "assetId": "cmnr12ih902cip658gn1xvrxy", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 17.24, "dayLow": 17.04, "volume": 5400547, "dayHigh": 17.78, "currency": "USD", "prevClose": 16.62, "week52Low": 15.73, "week52High": 32.68 }, "fundamentals": { "pe": -10.2192513368984, "beta": 0.627191912790155, "epsTTM": -1.87, "fcfTTM": -176000000, "growth": { "epsYoy": -0.4724409448818898, "revenueYoy": 0.0571643474990598 }, "sector": "Surgical & Medical Instruments & Apparatus", "margins": { "net": -0.08511205976520811, "gross": 0.3005158306652437, "operating": -0.02739238705087157 }, "website": "http://baxter.com", "industry": "Medical equipment", "pegRatio": -0.216307486631016, "ebitdaTTM": 536000000, "forwardPe": 8.20171673819742, "marketCap": 16000000000, "totalCash": 1966000000, "totalDebt": 9439000000, "debtEquity": 1.54005547397618, "quickRatio": 1.234343434343434, "revenueTTM": 11244000000, "companyName": "BAXTER INTERNATIONAL INC", "priceToBook": 1.60659292035398, "currentRatio": 2.313804713804714, "dividendYield": 0.0272353655812302, "returnOnAssets": -0.04771877337322363, "returnOnEquity": -0.156142927068037, "analystOpinions": null, "businessSummary": "Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion (+2% vs 2022), across three business: \"Medical Product and Therapies\", \"Healthcare Systems and Technologies\" and Pharmaceuticals.", "enterpriseValue": 17276430000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 38000, "sharesOutstanding": 514490045, "enterpriseToEbitda": 32.23214552238806, "analystTargetMedian": null, "enterpriseToRevenue": 1.536502134471718, "operatingCashflowTTM": 845000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:47.475Z" }, "results": [ { "id": "cmnr12iho02cop6588akhrgzx", "runId": "cmnr12ihm02cmp658ckehw5wo", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"BAX\",\"currency\":\"USD\",\"current_price\":17.24,\"target_price_6m\":18.75,\"target_price_12m\":20.0,\"recommendation\":\"BUY\",\"confidence\":0.55,\"thesis_bullets\":[\"Forward PE of 8.2x implies meaningful earnings recovery ahead\",\"Trading near 52-week low; ~47% below 52-week high of $32.68\",\"Heavy debt load of $9.4B constrains flexibility and amplifies risk\",\"Negative TTM earnings and FCF reflect ongoing restructuring headwinds\",\"Gradual margin recovery post-Vantive separation could unlock upside\"],\"key_drivers\":[{\"driver\":\"Post-Vantive restructuring and margin recovery trajectory\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction progress from divestiture proceeds\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Elevated leverage ($9.4B debt) limits strategic options\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Negative TTM free cash flow of -$176M\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Forward EPS implies >$2/share, major inflection from -$1.87 TTM\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Modest revenue growth of 5.7% YoY provides base stability\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low gross margin of 30% vs medtech peers\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield of 2.7% supports floor valuation\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Beta of 0.63 offers defensive profile in downturn\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Restructuring execution risk: margin recovery may take longer or fall short\",\"Debt servicing costs rise if rates stay elevated, pressuring earnings\",\"Potential dividend cut if FCF remains negative for multiple quarters\",\"Competitive pressure in medical products could compress gross margins\",\"Macro-driven hospital capex slowdown may weigh on revenue growth\"],\"assumptions\":{\"revenue_cagr_3y\":0.03,\"ebit_margin_target\":0.09,\"wacc\":0.09,\"terminal_multiple\":10.0},\"scenarios\":{\"bear\":{\"target_price\":13.5,\"prob\":0.25,\"notes\":\"Restructuring stalls, margins stay negative, debt overhang depresses multiple.\"},\"base\":{\"target_price\":20.0,\"prob\":0.50,\"notes\":\"Gradual margin recovery to mid-single-digit EBIT margins; debt reduction begins.\"},\"bull\":{\"target_price\":26.0,\"prob\":0.25,\"notes\":\"Successful turnaround yields ~9-10% EBIT margins; multiple re-rates toward medtech peers.\"}},\"method_notes\":\"Blended approach: forward PE on expected ~$2.10 FY EPS (implied by snapshot forwardPe of 8.2) at 9-10x multiple yields ~$19-21 base; cross-checked with EV/EBITDA on normalized ~$1.5B EBITDA less net debt. Heavy debt and negative TTM earnings cap confidence. Sell-side targets noted but not used as numeric inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Restructuring execution risk: margin recovery may take longer or fall short", "Debt servicing costs rise if rates stay elevated, pressuring earnings", "Potential dividend cut if FCF remains negative for multiple quarters", "Competitive pressure in medical products could compress gross margins", "Macro-driven hospital capex slowdown may weigh on revenue growth" ], "ticker": "BAX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual margin recovery to mid-single-digit EBIT margins; debt reduction begins.", "target_price": 20 }, "bear": { "prob": 0.25, "notes": "Restructuring stalls, margins stay negative, debt overhang depresses multiple.", "target_price": 13.5 }, "bull": { "prob": 0.25, "notes": "Successful turnaround yields ~9-10% EBIT margins; multiple re-rates toward medtech peers.", "target_price": 26 } }, "confidence": 0.55, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.03, "terminal_multiple": 10, "ebit_margin_target": 0.09 }, "key_drivers": [ { "driver": "Post-Vantive restructuring and margin recovery trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction progress from divestiture proceeds", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated leverage ($9.4B debt) limits strategic options", "impact": "HIGH", "direction": "NEG" }, { "driver": "Negative TTM free cash flow of -$176M", "impact": "HIGH", "direction": "NEG" }, { "driver": "Forward EPS implies >$2/share, major inflection from -$1.87 TTM", "impact": "HIGH", "direction": "POS" }, { "driver": "Modest revenue growth of 5.7% YoY provides base stability", "impact": "MED", "direction": "POS" }, { "driver": "Low gross margin of 30% vs medtech peers", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield of 2.7% supports floor valuation", "impact": "LOW", "direction": "POS" }, { "driver": "Beta of 0.63 offers defensive profile in downturn", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended approach: forward PE on expected ~$2.10 FY EPS (implied by snapshot forwardPe of 8.2) at 9-10x multiple yields ~$19-21 base; cross-checked with EV/EBITDA on normalized ~$1.5B EBITDA less net debt. Heavy debt and negative TTM earnings cap confidence. Sell-side targets noted but not used as numeric inputs. Not investment advice.", "current_price": 17.24, "recommendation": "BUY", "thesis_bullets": [ "Forward PE of 8.2x implies meaningful earnings recovery ahead", "Trading near 52-week low; ~47% below 52-week high of $32.68", "Heavy debt load of $9.4B constrains flexibility and amplifies risk", "Negative TTM earnings and FCF reflect ongoing restructuring headwinds", "Gradual margin recovery post-Vantive separation could unlock upside" ], "target_price_6m": 18.75, "target_price_12m": 20 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 38907, "createdAt": "2026-04-09T05:19:47.480Z", "usage": { "inputTokens": 3604, "outputTokens": 1896, "costUsd": 0.06542 } }, { "id": "cmnr12iho02crp658cetxbdli", "runId": "cmnr12ihm02cmp658ckehw5wo", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"BAX\",\n \"currency\": \"USD\",\n \"current_price\": 17.24,\n \"target_price_6m\": 19.0,\n \"target_price_12m\": 21.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Revenue growth sustained around 5% from medical demand.\",\n \"Cost initiatives to improve margins from negative to positive.\",\n \"Debt reduction expected to enhance financial flexibility.\",\n \"Valuation discount on forward earnings offers upside potential.\",\n \"Sector tailwinds from aging population support long-term growth.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue Growth\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Margin Expansion\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt Levels\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Free Cash Flow Generation\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Industry Demand\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive Pressure\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory Environment\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Product Innovation\", \"impact\": \"MED\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Continued profitability challenges and negative earnings.\",\n \"High debt burden limiting operational flexibility.\",\n \"Execution risk on cost-cutting and margin improvement.\",\n \"Macroeconomic factors affecting healthcare spending.\",\n \"Currency fluctuations due to global operations.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.03,\n \"wacc\": 0.08,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 12.6, \"prob\": 0.3, \"notes\": \"Earnings miss and multiple compression due to ongoing losses.\" },\n \"base\": { \"target_price\": 21.0, \"prob\": 0.5, \"notes\": \"Steady recovery with margin improvement and debt reduction.\" },\n \"bull\": { \"target_price\": 29.4, \"prob\": 0.2, \"notes\": \"Strong earnings beat and multiple expansion from faster growth.\" }\n },\n \"method_notes\": \"Valuation based on forward earnings and PE multiple expansion. BUY due to upside potential despite profitability risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Research Model", "risks": [ "Continued profitability challenges and negative earnings.", "High debt burden limiting operational flexibility.", "Execution risk on cost-cutting and margin improvement.", "Macroeconomic factors affecting healthcare spending.", "Currency fluctuations due to global operations." ], "ticker": "BAX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady recovery with margin improvement and debt reduction.", "target_price": 21 }, "bear": { "prob": 0.3, "notes": "Earnings miss and multiple compression due to ongoing losses.", "target_price": 12.6 }, "bull": { "prob": 0.2, "notes": "Strong earnings beat and multiple expansion from faster growth.", "target_price": 29.4 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.05, "terminal_multiple": 10, "ebit_margin_target": 0.03 }, "key_drivers": [ { "driver": "Revenue Growth", "impact": "MED", "direction": "POS" }, { "driver": "Margin Expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt Levels", "impact": "HIGH", "direction": "NEG" }, { "driver": "Free Cash Flow Generation", "impact": "MED", "direction": "POS" }, { "driver": "Industry Demand", "impact": "MED", "direction": "POS" }, { "driver": "Competitive Pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory Environment", "impact": "LOW", "direction": "NEG" }, { "driver": "Product Innovation", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on forward earnings and PE multiple expansion. BUY due to upside potential despite profitability risks. Not investment advice.", "current_price": 17.24, "recommendation": "BUY", "thesis_bullets": [ "Revenue growth sustained around 5% from medical demand.", "Cost initiatives to improve margins from negative to positive.", "Debt reduction expected to enhance financial flexibility.", "Valuation discount on forward earnings offers upside potential.", "Sector tailwinds from aging population support long-term growth." ], "target_price_6m": 19, "target_price_12m": 21 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 335, "createdAt": "2026-04-09T05:19:47.480Z", "usage": { "inputTokens": 2114, "outputTokens": 3786, "costUsd": 0.002182 } }, { "id": "cmnr12iho02cpp658qurdlbfp", "runId": "cmnr12ihm02cmp658ckehw5wo", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_Turnaround_v1\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"BAX\",\n \"currency\": \"USD\",\n \"current_price\": 17.24,\n \"target_price_6m\": 18.50,\n \"target_price_12m\": 20.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Valuation is highly compressed at 8.2x forward P/E, pricing in excessive execution risk.\",\n \"Portfolio streamlining focuses the company on higher-margin medical products and therapies.\",\n \"Debt reduction remains a priority, utilizing recent strategic actions to deleverage the balance sheet.\",\n \"TTM margins are depressed, but forward estimates suggest a strong profitability inflection.\",\n \"Dividend yield of 2.7% provides downside support while the turnaround strategy takes hold.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Forward EPS realization\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction and deleveraging\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital capital spending environment\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supply chain stabilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Post-spinoff stranded cost elimination\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate environment\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Failure to achieve projected forward earnings, leading to further multiple contraction.\",\n \"Slower-than-expected deleveraging if free cash flow remains negative.\",\n \"Continued hospital budget constraints impacting Healthcare Systems and Technologies sales.\",\n \"Integration and restructuring costs exceeding management guidance.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.14,\n \"wacc\": 0.085,\n \"terminal_multiple\": 11.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 14.00,\n \"prob\": 0.25,\n \"notes\": \"Turnaround stalls, margins remain depressed, and debt burden forces a dividend cut.\"\n },\n \"base\": {\n \"target_price\": 20.00,\n \"prob\": 0.55,\n \"notes\": \"Gradual margin recovery and successful deleveraging drive multiple expansion to 10x forward P/E.\"\n },\n \"bull\": {\n \"target_price\": 26.00,\n \"prob\": 0.20,\n \"notes\": \"Rapid realization of cost synergies and strong hospital capex drive earnings beats.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 10x forward P/E and DCF (8.5% WACC, 11x terminal multiple). The BUY rating reflects a 16% upside to our $20 PT, balancing the cheap valuation against near-term execution risks and negative TTM FCF. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "EquityResearch_Turnaround_v1", "risks": [ "Failure to achieve projected forward earnings, leading to further multiple contraction.", "Slower-than-expected deleveraging if free cash flow remains negative.", "Continued hospital budget constraints impacting Healthcare Systems and Technologies sales.", "Integration and restructuring costs exceeding management guidance." ], "ticker": "BAX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Gradual margin recovery and successful deleveraging drive multiple expansion to 10x forward P/E.", "target_price": 20 }, "bear": { "prob": 0.25, "notes": "Turnaround stalls, margins remain depressed, and debt burden forces a dividend cut.", "target_price": 14 }, "bull": { "prob": 0.2, "notes": "Rapid realization of cost synergies and strong hospital capex drive earnings beats.", "target_price": 26 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 11, "ebit_margin_target": 0.14 }, "key_drivers": [ { "driver": "Forward EPS realization", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction and deleveraging", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Hospital capital spending environment", "impact": "MED", "direction": "POS" }, { "driver": "Supply chain stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Post-spinoff stranded cost elimination", "impact": "MED", "direction": "POS" }, { "driver": "Interest rate environment", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 10x forward P/E and DCF (8.5% WACC, 11x terminal multiple). The BUY rating reflects a 16% upside to our $20 PT, balancing the cheap valuation against near-term execution risks and negative TTM FCF. Not investment advice.", "current_price": 17.24, "recommendation": "BUY", "thesis_bullets": [ "Valuation is highly compressed at 8.2x forward P/E, pricing in excessive execution risk.", "Portfolio streamlining focuses the company on higher-margin medical products and therapies.", "Debt reduction remains a priority, utilizing recent strategic actions to deleverage the balance sheet.", "TTM margins are depressed, but forward estimates suggest a strong profitability inflection.", "Dividend yield of 2.7% provides downside support while the turnaround strategy takes hold." ], "target_price_6m": 18.5, "target_price_12m": 20 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25275, "createdAt": "2026-04-09T05:19:47.480Z", "usage": { "inputTokens": 2474, "outputTokens": 891, "costUsd": 0.01564 } }, { "id": "cmnr12iho02cnp658zc923k5p", "runId": "cmnr12ihm02cmp658ckehw5wo", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI Equity Model v2\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"BAX\",\"currency\":\"USD\",\"current_price\":17.24,\"target_price_6m\":18.4,\"target_price_12m\":19,\"recommendation\":\"BUY\",\"confidence\":0.63,\"thesis_bullets\":[\"Vantive sale should cut leverage and simplify Baxter's portfolio.\",\"Forward valuation appears compressed versus normalized earnings potential.\",\"Operational fixes can lift margins from depressed, charge-heavy levels.\",\"Negative TTM EPS and FCF show the turnaround is incomplete.\",\"Upside exists, but execution and quality risks justify only moderate conviction.\"],\"key_drivers\":[{\"driver\":\"Vantive proceeds deleveraging\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin recovery from productivity actions\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medication delivery demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing versus input inflation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Working-capital and FCF normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Residual separation stranded costs\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Quality or recall expenses\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Debt and interest burden\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Margin recovery takes longer than planned\",\"Product quality, recall, or regulatory issues\",\"Hospital spending softness reduces demand\",\"Separation costs and stranded overhead persist\",\"Leverage restrains capital allocation\"],\"assumptions\":{\"revenue_cagr_3y\":2.8,\"ebit_margin_target\":10,\"wacc\":9.3,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":14.5,\"prob\":0.25,\"notes\":\"Recovery stalls, separation drag lingers, and cash conversion stays weak.\"},\"base\":{\"target_price\":19.2,\"prob\":0.55,\"notes\":\"Deleveraging and execution improve margins, but rerating remains limited.\"},\"bull\":{\"target_price\":24,\"prob\":0.2,\"notes\":\"Faster productivity gains and cleaner portfolio drive a sharper rerating.\"}},\"method_notes\":\"12M target uses scenario-weighted EV/EBITDA and FCF normalization anchored to snapshot cash, debt and shares. Snapshot quote/fundamentals were kept authoritative; no sell-side targets used as inputs. BUY reflects ~10% 12M upside with material execution risk; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "OpenAI Equity Model v2", "risks": [ "Margin recovery takes longer than planned", "Product quality, recall, or regulatory issues", "Hospital spending softness reduces demand", "Separation costs and stranded overhead persist", "Leverage restrains capital allocation" ], "ticker": "BAX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Deleveraging and execution improve margins, but rerating remains limited.", "target_price": 19.2 }, "bear": { "prob": 0.25, "notes": "Recovery stalls, separation drag lingers, and cash conversion stays weak.", "target_price": 14.5 }, "bull": { "prob": 0.2, "notes": "Faster productivity gains and cleaner portfolio drive a sharper rerating.", "target_price": 24 } }, "confidence": 0.63, "assumptions": { "wacc": 9.3, "revenue_cagr_3y": 2.8, "terminal_multiple": 10.5, "ebit_margin_target": 10 }, "key_drivers": [ { "driver": "Vantive proceeds deleveraging", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin recovery from productivity actions", "impact": "HIGH", "direction": "POS" }, { "driver": "Medication delivery demand", "impact": "MED", "direction": "POS" }, { "driver": "Pricing versus input inflation", "impact": "MED", "direction": "POS" }, { "driver": "Working-capital and FCF normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Residual separation stranded costs", "impact": "MED", "direction": "NEG" }, { "driver": "Quality or recall expenses", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt and interest burden", "impact": "MED", "direction": "NEG" } ], "method_notes": "12M target uses scenario-weighted EV/EBITDA and FCF normalization anchored to snapshot cash, debt and shares. Snapshot quote/fundamentals were kept authoritative; no sell-side targets used as inputs. BUY reflects ~10% 12M upside with material execution risk; not investment advice.", "current_price": 17.24, "recommendation": "BUY", "thesis_bullets": [ "Vantive sale should cut leverage and simplify Baxter's portfolio.", "Forward valuation appears compressed versus normalized earnings potential.", "Operational fixes can lift margins from depressed, charge-heavy levels.", "Negative TTM EPS and FCF show the turnaround is incomplete.", "Upside exists, but execution and quality risks justify only moderate conviction." ], "target_price_6m": 18.4, "target_price_12m": 19 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0884be8c6820bd120069d7567043ac8193980eee452650bfcf", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 61017, "createdAt": "2026-04-09T05:19:47.480Z", "usage": { "inputTokens": 2387, "outputTokens": 3462, "costUsd": 0.052645 } }, { "id": "cmnr12iho02cqp6587io2h44x", "runId": "cmnr12ihm02cmp658ckehw5wo", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"BAX\",\n \"currency\": \"USD\",\n \"current_price\": 17.24,\n \"target_price_6m\": 18.8,\n \"target_price_12m\": 20.5,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.58,\n \"thesis_bullets\": [\n \"Negative FCF and margins reflect ongoing operational issues\",\n \"Forward P/E of 8.2x signals undervaluation on recovery\",\n \"Stable 5% revenue growth in medical products segment\",\n \"High debt burden limits flexibility and raises risk\",\n \"Restructuring and pipeline offer path to margin expansion\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"EBIT margin recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Negative FCF persistence\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Revenue CAGR stabilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Product pipeline execution\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital budget pressures\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory approvals\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged negative free cash flow\",\n \"High leverage and interest costs\",\n \"Supply chain and cost inflation\",\n \"Competition in medtech segments\",\n \"Regulatory or litigation setbacks\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 4.5,\n \"ebit_margin_target\": 12,\n \"wacc\": 8.7,\n \"terminal_multiple\": 13.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 14.2,\n \"prob\": 0.35,\n \"notes\": \"Margins stay negative with weak demand.\"\n },\n \"base\": {\n \"target_price\": 20.5,\n \"prob\": 0.45,\n \"notes\": \"Gradual margin recovery and FCF improvement.\"\n },\n \"bull\": {\n \"target_price\": 26.0,\n \"prob\": 0.2,\n \"notes\": \"Strong execution beats estimates significantly.\"\n }\n },\n \"method_notes\": \"3-stage DCF using revenue CAGR, target EBIT margin, WACC and terminal multiple; forward valuation supports modest upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Research Model", "risks": [ "Prolonged negative free cash flow", "High leverage and interest costs", "Supply chain and cost inflation", "Competition in medtech segments", "Regulatory or litigation setbacks" ], "ticker": "BAX", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Gradual margin recovery and FCF improvement.", "target_price": 20.5 }, "bear": { "prob": 0.35, "notes": "Margins stay negative with weak demand.", "target_price": 14.2 }, "bull": { "prob": 0.2, "notes": "Strong execution beats estimates significantly.", "target_price": 26 } }, "confidence": 0.58, "assumptions": { "wacc": 8.7, "revenue_cagr_3y": 4.5, "terminal_multiple": 13.5, "ebit_margin_target": 12 }, "key_drivers": [ { "driver": "EBIT margin recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Negative FCF persistence", "impact": "HIGH", "direction": "NEG" }, { "driver": "Revenue CAGR stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction progress", "impact": "MED", "direction": "POS" }, { "driver": "Product pipeline execution", "impact": "MED", "direction": "POS" }, { "driver": "Hospital budget pressures", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approvals", "impact": "LOW", "direction": "POS" } ], "method_notes": "3-stage DCF using revenue CAGR, target EBIT margin, WACC and terminal multiple; forward valuation supports modest upside. Not investment advice.", "current_price": 17.24, "recommendation": "BUY", "thesis_bullets": [ "Negative FCF and margins reflect ongoing operational issues", "Forward P/E of 8.2x signals undervaluation on recovery", "Stable 5% revenue growth in medical products segment", "High debt burden limits flexibility and raises risk", "Restructuring and pipeline offer path to margin expansion" ], "target_price_6m": 18.8, "target_price_12m": 20.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "c34fc7e2-55f4-9f06-a6d7-e676e9b9e787", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 13827, "createdAt": "2026-04-09T05:19:47.480Z", "usage": { "inputTokens": 2723, "outputTokens": 3119, "costUsd": 0.054954 } } ] } }